RedPath’s
PathFinderTG®

represents over 17 years of research and development and is clinically validated at an average 95% accuracy
rate across multiple organs, specimen types and diagnostic questions
for cancer.
Physicians: PathFinderTG®

 

RedPath Integrated Pathology’s PathFinderTG: Leading edge, molecular-based cancer diagnostic testing:

• Combines advances in molecular genetics with current pathology practices for an integrated approach

• Provides objective, accurate and comprehensive analysis

• Leverages advances in imaging and sampling techniques by working with the most minute tissue, cytology and fluid samples

• Facilitates personalized medicine where the unique DNA fingerprint of a tumor allows for early and definitive diagnosis and individualized patient care

Clinically Validated

Because PathFinderTG has been clinically validated and peer-reviewed, you can have confidence in its quality, accuracy, and individualized results.

  • 95% accuracy rate across validated clinical applications
  • 17 years in development and clinical use
  • 15,000+ clinical specimens analyzed
  • 129+ peer reviewed medical journal publications


Easy to use

  • Complements traditional pathology practice by integrating morphology with molecular analysis
  • Results are available within 5 business days
  • No special collection procedures
    - Standard histology slides of fixed, embedded tissues
    - Stained cytology slides, even those with few cells
    - Fine needle aspirates (FNAs)
    - Body fluids, effusions, ascites and cyst aspirates
    - Archived, fixed and/or frozen specimens
  • RedPath only bills hospitals when required by law
  • RedPath never bills physicians unless requested by the physician
  • Final report is clear and easy to understand


The PathFinderTG report is a comprehensive description that incorporates the morphologic review with the molecular analysis in a form that is easily understood and meets CAP guidelines.  A written summary of the number and type of mutations found, if any, is provided and the temporal sequence of mutation acquisition is described.   A diagnosis with detailed commentary including a summary of the molecular profile of the patient’s specimen is provided in the context of available clinical history and pathology information. The report is delivered via fax.